↓ Skip to main content

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Overview of attention for article published in Blood, April 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news
2 news outlets
twitter
8 X users
patent
1 patent

Citations

dimensions_citation
205 Dimensions

Readers on

mendeley
130 Mendeley